Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine.
In this study, we compare cholesterol levels during the first year after renal transplantation in FK506 (Prograf)- and cyclosporine-treated patients matched for cumulative first-year steroid dose and hypercholesterolemia risk factors. All patients had pretransplant cholesterol levels < 200 mg/dl. At 3 months posttransplant, 68% of the cyclosporine-treated patients had at least one cholesterol level greater than 200 mg/dl compared with 30% of the FK506-treated patients (P < 0.05). At the end of the year, 26% of FK506- and 67% of cyclosporine-treated patients remained hypercholesterolemic (P < 0.05). We conclude that cyclosporine has inherently more effect on cholesterol levels than FK506 during the first year after kidney transplantation.
Satterthwaite
R
R
National Institute of Transplantation, Los Angeles, California 90057, USA.
Aswad
S
S
Sunga
V
V
Shidban
H
H
Bogaard
T
T
Asai
P
P
Khetan
U
U
Akra
I
I
Mendez
R G
RG
Mendez
R
R
D000328:Adult; D000367:Age Factors; D002784:Cholesterol / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects*; D003922:Diabetes Mellitus, Type 1 / Q000453:epidemiology; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D006937:Hypercholesterolemia / Q000139:chemically induced / Q000453:epidemiology*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000139:chemically induced / Q000453:epidemiology*; D012189:Retrospective Studies; D012737:Sex Factors; D016559:Tacrolimus / Q000009:adverse effects*
D007166:Immunosuppressive Agents; D005665:Furosemide; D016572:Cyclosporine; D002784:Cholesterol; D016559:Tacrolimus